ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
25.25
-1.31 (-4.93%)
At close: Mar 5, 2026, 4:00 PM EST
24.50
-0.75 (-2.97%)
After-hours: Mar 5, 2026, 7:15 PM EST
ArriVent BioPharma Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for ArriVent BioPharma stock have an average target of 39.2, with a low estimate of 31 and a high estimate of 45. The average target predicts an increase of 55.25% from the current stock price of 25.25.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 10, 2025.
Analyst Ratings
The average analyst rating for ArriVent BioPharma stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 9 | 9 | 9 | 9 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 23, 2025 |
| BTIG | BTIG | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +78.22% | Dec 10, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $43 | Strong Buy | Initiates | $43 | +70.30% | Nov 25, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $33 → $31 | Strong Buy | Maintains | $33 → $31 | +22.77% | Nov 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $42 | Strong Buy | Maintains | $40 → $42 | +66.34% | Aug 12, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
428.40K
EPS This Year
-4.44
from -2.56
EPS Next Year
-3.92
from -4.44
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 4.4M | ||||
| Avg | n/a | 428,400 | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -4.24 | -2.90 | ||||
| Avg | -4.44 | -3.92 | ||||
| Low | -4.35 | -5.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.